NetworkNewsWire Announces Publication Discussing Advances in Cannabinoids for use in Pain Management
New York, New York--(Newsfile Corp. - December 11, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
The publication, titled, "Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management," discusses advances in the development of cannabinoid-based topical therapies for use in alleviating pain without psychoactive side effects.
To view the full publication, visit: https://www.networknewswire.com/advanced-biosynthesis-setting-new-standards-cannabinoid-based-pain-management
"Pre-clinical results in the development of the company's INM-405 candidate for the treatment of pain suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders such as temporomandibular disorders (TMD) and trigeminal neuralgia (TN) - without any observed central nervous system side effects.
"TN in particular is known for symptoms involving intense and uncontrollable face and jaw spasms, causing pain that is so severe it has been nicknamed "the suicide disease." It is estimated that 12 new cases of TN occur per 100,000 persons every year, according to the National Institute of Neurological Disorders and Stroke. Sufferers have found some relief smoking marijuana, but must do so frequently and are subject to protracted psycho-activity caused by THC. InMed recognizes the need and market opportunity for non-opioid alternatives to treat chronic and severe pain with limited side effects.
"InMed has since filed a provisional patent application for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain (http://nnw.fm/K0MRo), noting the need for therapies centered on specific non-psychoactive cannabinoids."
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company. For more information, visit www.InMedPharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.